Pilot Study of Exenatide Pharmacokinetics and Pharmacodynamics in Gestational Diabetes
NCT00572689 on ClinicalTrials.gov · last registry update 2015-08-21
Withdrawn before anyone was enrolled. The sponsor logged completion for August 2015. Primary outcome, as filed: glycemic control through insulin, glucose, c-peptide and glucagon assays.
- Status
- WITHDRAWN
- Phase
- P4
- Drug
- exenatideBydureon, Byetta
- Sponsor
- Georgetown University
- Sponsor type
- Other
- Enrollment
- 0
- Started
- 2013-08
- Primary completion
- 2015-08 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
glycemic control through insulin, glucose, c-peptide and glucagon assays
Conditions studied
Gestational Diabetes
Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.